Martine Rothblatt Sells 8,984 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 8,984 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $537.97, for a total transaction of $4,833,122.48. Following the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $69,936.10. This trade represents a 98.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Up 1.1%

Shares of UTHR opened at $540.02 on Wednesday. The company has a 50 day moving average of $488.31 and a two-hundred day moving average of $465.54. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $548.12. The company has a market cap of $23.67 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the firm posted $6.19 earnings per share. The business’s quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. AE Wealth Management LLC boosted its stake in shares of United Therapeutics by 7.6% during the 2nd quarter. AE Wealth Management LLC now owns 864 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 61 shares in the last quarter. Allworth Financial LP grew its holdings in shares of United Therapeutics by 147.2% in the 2nd quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 212 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of United Therapeutics by 6.4% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 16,833 shares of the biotechnology company’s stock worth $4,837,000 after acquiring an additional 1,006 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in United Therapeutics by 8.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 11,589 shares of the biotechnology company’s stock valued at $3,330,000 after purchasing an additional 917 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. HC Wainwright upped their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Finally, TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $548.09.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.